TERN

Terns Pharmaceuticals, Inc.

6.73 USD

Last updated Dec 10, 04:55 UTC

Yesterday HIGH

$6.91

Yesterday LOW

$6.45

52w HIGH

$14.04

52w LOW

$3.26

EPS

-0.42

PE

-16.02

Next Earnings

Mar 25, 2024

Overview News Insider Transactions Government Trades

Terns Pharmaceuticals, Inc. stock is up 91.19% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

Terns Pharmaceuticals, Inc. develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

ternspharma.com

richadhand@benzinga.com

Fri Jun 30, 2023

JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $17 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $17 price target.
richadhand@benzinga.com

Fri Jun 30, 2023

Mizuho Reiterates Buy on Terns Pharma, Maintains $16 Price Target

Mizuho analyst Graig Suvannavejh reiterates Terns Pharma (NASDAQ:TERN) with a Buy and maintains $16 price target.
Vandana Singh

Wed Jun 28, 2023

Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says

Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was p
Lisa Levin

Tue Jun 27, 2023

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Benzinga Insights

Tue Jun 27, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
richadhand@benzinga.com

Tue Jun 27, 2023

Mizuho Reiterates Buy on Terns Pharma, Maintains $16 Price Target

Mizuho analyst Graig Suvannavejh reiterates Terns Pharma (NASDAQ:TERN) with a Buy and maintains $16 price target.
Happy Mohamed

Mon Jun 26, 2023

Terns Pharmaceuticals Highlights New Preclinical Data For TERN-601 Program In Obesity At The ADA's 83rd Annual Scientific Session And Upcoming Events

TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model Company to participate in upcoming Piper Sandler Inaugural Obesity
Benzinga Insights

Thu Jun 22, 2023

Expert Ratings for Terns Pharma
Vandana Singh

Thu Jun 22, 2023

Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation

Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,
Benzinga Insights

Thu Jun 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023

JP Morgan

Tue Dec 5, 09:28

buy

confirm
Mizuho

Mon Nov 27, 11:34

buy

confirm

Advanced Data Unlock

Yoon Seokho Bryan, COO and General Counsel

Thu Nov 30, 2023

TERN Recent Insider Trades and Stock Chart

743 shares bought
Vignola Mark J., Chief Financial Officer

Thu Nov 30, 2023

TERN Recent Insider Trades and Stock Chart

743 shares bought
Quigley Jill M., Director

Wed Nov 15, 2023

TERN Recent Insider Trades and Stock Chart

15,000 shares awarded